The 3'UTR signature defines a highly metastatic subgroup of triple-negative breast cancer

26Citations
Citations of this article
35Readers
Mendeley users who have this article in their library.

Abstract

Triple-negative breast cancer (TNBC) is a highly heterogeneous disease with an aggressive clinical course. Prognostic models are needed to chart potential patient outcomes. To address this, we used alternative 3'UTR patterns to improve postoperative risk stratification. We collected 327 publicly available microarrays and generated the 3'UTR landscape based on expression ratios of alternative 3'UTR. After initial feature filtering, we built a 17-3'UTR-based classifier using an elastic net model. Time-dependent ROC comparisons and Kaplan-Meier analyses confirmed an outstanding discriminating power of our prognostic model for TNBC patients. In the training cohort, 5-year event-free survival (EFS) was 78.6% (95% CI 71.2-86.0) for the low-risk group, and 16.3% (95% CI 2.3-30.4) for the high-risk group (log-rank p < 0.0001; hazard ratio [HR] 8.29, 95% CI 4.78-14.4), In the validation set, 5-year EFS was 75.6% (95% CI 68.0-83.2) for the low-risk group, and 33.2% (95% CI 17.1- 49.3) for the high-risk group (log-rank p < 0.0001; HR 3.17, 95% CI 1.66-5.42). In conclusion, the 17-3'UTR-based classifier provides a superior prognostic performance for estimating disease recurrence and metastasis in TNBC patients and it may permit personalized management strategies.

Cite

CITATION STYLE

APA

Wang, L., Hu, X., Wang, P., & Shao, Z. M. (2016). The 3’UTR signature defines a highly metastatic subgroup of triple-negative breast cancer. Oncotarget, 7(37), 59834–59844. https://doi.org/10.18632/oncotarget.10975

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free